BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36716502)

  • 1. Complementary Role of 18 F-Fluciclovine PET/CT and 18 F-NaF PET/CT in Detecting Prostate Cancer Metastasis.
    Xu F; Liu F; Chen W
    Clin Nucl Med; 2023 Apr; 48(4):330-331. PubMed ID: 36716502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.
    Chen B; Wei P; Macapinlac HA; Lu Y
    Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Additional Primary Neoplasms on
    Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
    J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
    Kim EH; Siegel BA; Teoh EJ; Andriole GL;
    Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Utility of
    Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
    Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best Practices for
    Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
    J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
    [No Abstract]   [Full Text] [Related]  

  • 9. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.
    Chen B; Macapinlac HA; Lu Y
    Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extraprostatic Uptake of
    Robertson MS; Sakellis CG; Hyun H; Jacene HA
    AJR Am J Roentgenol; 2020 Mar; 214(3):641-648. PubMed ID: 31939697
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
    Chau A; Gardiner P; Colletti PM; Jadvar H
    Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Response to Lycopene in Recurrent Prostate Cancer Confirmed on 18 F-Fluciclovine PET/CT.
    Wu C; Marcus C; Baum Y; Kucuk O; Schuster DM
    Clin Nucl Med; 2023 Apr; 48(4):361-363. PubMed ID: 36728146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
    Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
    J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
    [No Abstract]   [Full Text] [Related]  

  • 14. A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.
    Pernthaler B; Kulnik R; Gstettner C; Salamon S; Aigner RM; Kvaternik H
    Clin Nucl Med; 2019 Oct; 44(10):e566-e573. PubMed ID: 31283605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-Fluciclovine PET/CT: A Potential Imaging Biomarker for the Evaluation of Multiple Myeloma.
    Marcus C; Schuster DM; Tajmir SH
    Clin Nucl Med; 2022 Sep; 47(9):e613-e615. PubMed ID: 35930716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis.
    Qi J; Nguyen NC
    Clin Nucl Med; 2022 Dec; 47(12):1061-1062. PubMed ID: 36026595
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences.
    Hwang L; Paluch J; Jadvar H; England JR; Desai B; Ballas LK
    Clin Nucl Med; 2020 Sep; 45(9):668-671. PubMed ID: 32520496
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.